DUREN GUTIERREZ: Open Payments
NPI 1598003915 · SOUTHFIELD, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$72,186 in 206 payments from 11 companies in 2025. Trend: 2023 $59,128 · 2024 $66,880 · 2025 $72,186
Speaker / faculty: $53,139Consulting: $10,781Travel & lodging: $4,720Food & beverage: $3,531Education: $15
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 59 | $46,844 |
| Alkermes, Inc. | 37 | $9,251 |
| Teva Pharmaceuticals USA, Inc. | 13 | $6,821 |
| E.R. Squibb & Sons, L.L.C. | 38 | $5,000 |
| ABBVIE INC. | 20 | $3,598 |
| Otsuka America Pharmaceutical, Inc. | 18 | $268 |
| Indivior Inc. | 8 | $198 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $82 |
| Neurocrine BioSciences, Inc. | 5 | $79 |
| Vanda Pharmaceuticals Inc. | 2 | $29 |
Products named: INVEGA SUSTENNA, LYBALVI, UZEDY, VRAYLAR, COBENFY, ARISTADA, SUBLOCADE, REXULTI.
Industry payments across MI — which companies pay providers there.
